- Home
- TENB vs APLS Comparison
TENB vs APLS Comparison
Compare TENB & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TENB | APLS |
|---|---|---|
| Founded | 2002 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.7B |
| IPO Year | 2018 | 2015 |
Fundamental Metrics
Financial Performance| Metric | TENB | APLS |
|---|---|---|
| Price | $20.17 | $18.84 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 21 |
| Target Price | ★ $34.70 | $31.85 |
| AVG Volume (30 Days) | ★ 2.4M | 1.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.23 | ★ 112.50 |
| EPS | N/A | ★ 0.20 |
| Revenue | $999,405,000.00 | ★ $1,003,782,000.00 |
| Revenue This Year | $9.37 | N/A |
| Revenue Next Year | $7.04 | $17.97 |
| P/E Ratio | ★ N/A | $95.38 |
| Revenue Growth | 11.04 | ★ 28.46 |
| 52 Week Low | $17.28 | $16.10 |
| 52 Week High | $37.90 | $30.48 |
Technical Indicators
Market Signals| Indicator | TENB | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 45.10 | 32.57 |
| Support Level | $19.15 | $17.16 |
| Resistance Level | $21.29 | $20.42 |
| Average True Range (ATR) | 0.90 | 0.74 |
| MACD | 0.10 | -0.14 |
| Stochastic Oscillator | 62.55 | 13.72 |
Price Performance
Historical ComparisonAbout TENB Tenable Holdings Inc.
Founded in 2002, Tenable is a cybersecurity company that began providing vulnerability management solutions under its Nessus software. In recent years, Tenable has expanded its portfolio to provide a broader range of exposure management modules. Solutions include cloud security and compliance, active directory management, operational technology security and advanced vulnerability analytics. The Maryland-based company went public in 2018.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.